New Zealand markets open in 9 hours 56 minutes

RPRX Dec 2022 30.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.40000.0000 (0.00%)
As of 08:30AM EST. Market open.
Full screen
Previous close0.4000
Open0.4000
Bid0.0000
Ask0.0000
Strike30.00
Expiry date2022-12-16
Day's range0.4000 - 0.4000
Contract rangeN/A
Volume1
Open interest9
  • Simply Wall St.

    Is Royalty Pharma plc (NASDAQ:RPRX) Trading At A 50% Discount?

    Does the December share price for Royalty Pharma plc ( NASDAQ:RPRX ) reflect what it's really worth? Today, we will...

  • GlobeNewswire

    Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

    NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma

  • GlobeNewswire

    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

    Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasd